AU4100699A - Compositions and methods employing r(-) fluoxetine and other active ingredients - Google Patents

Compositions and methods employing r(-) fluoxetine and other active ingredients

Info

Publication number
AU4100699A
AU4100699A AU41006/99A AU4100699A AU4100699A AU 4100699 A AU4100699 A AU 4100699A AU 41006/99 A AU41006/99 A AU 41006/99A AU 4100699 A AU4100699 A AU 4100699A AU 4100699 A AU4100699 A AU 4100699A
Authority
AU
Australia
Prior art keywords
fluoxetine
compositions
active ingredients
methods employing
employing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41006/99A
Inventor
Timothy J Barberich
Dean A. Handley
Paul D. Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU4100699A publication Critical patent/AU4100699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
AU41006/99A 1998-05-28 1999-05-27 Compositions and methods employing r(-) fluoxetine and other active ingredients Abandoned AU4100699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8626298A 1998-05-28 1998-05-28
US09086262 1998-05-28
PCT/US1999/011725 WO1999061014A2 (en) 1998-05-28 1999-05-27 Compositions and methods employing r(-) fluoxetine and other active ingredients

Publications (1)

Publication Number Publication Date
AU4100699A true AU4100699A (en) 1999-12-13

Family

ID=22197368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41006/99A Abandoned AU4100699A (en) 1998-05-28 1999-05-27 Compositions and methods employing r(-) fluoxetine and other active ingredients

Country Status (2)

Country Link
AU (1) AU4100699A (en)
WO (1) WO1999061014A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566065B1 (en) * 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6312717B1 (en) * 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
WO2000024399A1 (en) * 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
CA2352611A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
AU2002232470B2 (en) 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
EP1423104A1 (en) * 2001-08-08 2004-06-02 Eli Lilly And Company Combination therapy for the treatment of neurological disorders
WO2006110642A2 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
CN103502224A (en) 2011-02-23 2014-01-08 克鲁莱斯有限公司 Flumazenil complexes, compositions comprising same and uses thereof
EP3024451A4 (en) * 2013-06-24 2017-08-16 The Johns Hopkins University Methods for reducing anxiety and impulsivity in subjects initiating treatment with serotonin reuptake inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
CA2039103A1 (en) * 1990-03-29 1991-09-30 David Wayne Robertson Improvements in and relating to the selective occupation of serotonin 1c receptors
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
AU1429092A (en) * 1991-02-04 1992-09-07 Timothy J Barberich Methods of use and compositions of r(-) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
SE9501567D0 (en) * 1995-04-27 1995-04-27 Astra Ab A new combination
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders

Also Published As

Publication number Publication date
WO1999061014A2 (en) 1999-12-02
WO1999061014A3 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
AU7429100A (en) Chondrocyte compositions, preparation and use thereof
AU4099199A (en) Encapsulated breakers, compositions and methods of use
AU1458300A (en) Simultaneous cleaning and decontaminating compositions and methods
AU3572599A (en) Analgesic compositions comprising nmda-antagonists and abt-594
AU2487699A (en) Alteration of amino acid compositions in seeds
AU2091499A (en) Permeable compositions and methods for their preparation
AU3671099A (en) Methods and compositions pertaining to pd-loops
AU5270499A (en) Formulations having probiotically active microorganisms
AU2349399A (en) R-lansoprazole compositions and methods
HK1041639A1 (en) Stable amorphous amifostine compositions and methods for the preparation and use of same.
AU2660900A (en) 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclyl-pyrimidines and their use as repellents
AU5565099A (en) Pharmaceutical compositions and methods for use
AU4100699A (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
AU1321900A (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
AU6408898A (en) Antimicrobial compositions, their preparation and use
AU2184099A (en) Insecticidal compositions and insecticidal methods
AU4996100A (en) (s,r) formoterol methods and compositions
AU5965399A (en) Pharmaceutically active composition
EP1075184A4 (en) Compositions and methods for active vaccination
AU4981199A (en) Compositions and methods for modulating sexual activity
AU6033696A (en) Detergent compositions comprising polyamine scavenger agents and enzymes
AU1558700A (en) Combinations of active ingredients
AU5032499A (en) Dye-transfer-inhibiting compositions and particulate detergent compositions containing them
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU3558799A (en) Flutamide compositions and preparations

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase